Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Lanman, Richard B ^a   Mortimer, Stefanie A ^a   Zill, Oliver A ^a   Sebisanovic, Dragan ^a   Lopez, Rene ^a   Blau, Sibel ^b   Collisson, Eric A ^c   Divers, Stephen G ^d   Hoon, Dave S B ^e   Scott Kopetz, E ^f   Lee, Jeeyun ^g   Nikolinakos, Petros G ^h   Baca, Arthur M ^a   Kermani, Bahram G ^a   Eltoukhy, Helmy ^a   Talasaz, Amir Ali ^a  

^a Guardant Health   (United States)

^b Northwest Medical Specialties   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Genesis Cancer Center   (United States)

^e JOHN WAYNE CANCER INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g Sungkyunkwan University School of Medicine   (South Korea)

^h University Cancer and Blood Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FREE CIRCULATING TUMOR DNA; DNA; DNA FRAGMENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COPY NUMBER VARIATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL SEQUENCING; DNA DETERMINATION; DNA SEQUENCE; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENETIC PARAMETERS; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; MUTANT ALLELE FRACTION; NEXT GENERATION SEQUENCING; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SINGLE NUCLEOTIDE VARIANT; UROGENITAL TRACT CANCER; VALIDATION STUDY; WHOLE EXOME SEQUENCING; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; GENETICS; HIGH THROUGHPUT SEQUENCING; NEOPLASM; PROCEDURES;

DNA, NEOPLASM; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; NEOPLASMS;

EID: 84949009842     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0140712     Document Type: Article

References (81)

1. Non-Small Cell Lung Cancer (Version 4.2014) [Internet]. 2014. Available: http://www.nccn.org/professionals/physician-gls/pdf/nscl.pdf
2. Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, et al. NCCN Working Group Report-Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies. J Natl Compr Canc Netw. 2014; 12: S1-S21. PMID: 24614042
3. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013; 501: 338-45. doi: 10.1038/nature12625 PMID: 24048066
4. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med. 2013; 137: 685-705. doi: 10.5858/arpa.2012-0264-RA PMID: 22913371
5. National Lung Cancer Audit Report 2012 [Internet]. 2012. Available: http://www.hqip.org.uk/assets/NCAPOP-Library/NCAPOP-2012-13/Lung-Cancer-National-Audit-Report-pub-2012.pdf
6. Rosen S. World Market for Cancer Diagnostics, 5th Edition. 2013.
7. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger K, Yatabe Y, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc. 2011; 8: 381-5. doi: 10.1513/pats.201107-042ST PMID: 21926387
8. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba I, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014; 311:1998-2006. doi: 10. 1001/jama.2014.3741 PMID: 24846037
9. Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012; 30: 587-92. doi: 10.1200/JCO.2010.33.5232 PMID: 22124102
10. Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, et al. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer. 2014; doi: 10.1002/cncr.29089 PMID: 26437205
11. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012; 72: 4875-82. doi: 10.1158/0008-5472.CAN-12-2217 PMID: 23002210
12. Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, et al. Tumor clone dynamics in lethal prostate cancer. Sci Transl Med. 2014; 6: 254ra125. doi: 10.1126/scitranslmed.3009448 PMID: 25232177
13. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012; 366: 883-92. doi: 10.1056/NEJMoa1113205 PMID: 22397650
14. Govindan R. Cancer. Attack of the clones. Science. 2014; 346:169-170. doi: 10.1126/science. 1259926 PMID: 25301605
15. Mandel P, Metais P. Les acides nucléiques du plasma sanguin chez l'homme. CR Acad Sci Paris. 1948; 142: 241-3.
16. Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol. 1987; 23: 707-712. PMID: 3653190
17. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011; 11: 426-37. doi: 10.1038/nrc3066 PMID: 21562580
18. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature. 1980; 284: 555-556. PMID: 6245367
19. Chandrananda D, Thorne NP, Bahlo M. High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA. BMC Med Genomics. 2015; 8: 29. doi: 10.1186/s12920-015-0107-z PMID: 26081108
20. Fleischhacker M, Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta. 2007; 1775:181-232. doi: 10.1016/j.bbcan.2006.10.001 PMID: 17137717
21. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008; 14: 985-90. doi: 10.1038/nm. 1789 PMID: 18670422
22. Lo YM, Tein MS, Lau TK, Haines CJ, Leung TN, Poon PM, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet. 1998; 62: 768-775. doi: 10.1086/301800 PMID: 9529358
23. Talasaz Amir Ali, Mortimer Stephanie, Schiller Benjamin J., Mei Gangwei, Sebisanovic Dragan, Siew Lai Mun, et al. Non-invasive and sequential profiling of metastatic solid tumors by Digital Sequencing of cell-free DNA [Abstract 3422S]. Am Soc Hum Genet Annu Meet. 2014; Available: http://www.ashg.org/2013meeting/pdf/46025 Poster bookmark%20for%20Web%20final%20from%20AGS.pdf
24. Luke JJ, Oxnard GR, Paweletz CP, Camidge DR, Heymach JV, Solit DB, et al. Realizing the potential of plasma genotyping in an age of genotype-directed therapies. J Natl Cancer Inst. 2014;106. doi: 10. 1093/jnci/dju214
25. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014; 32: 579-86. doi: 10.1200/JCO.2012.45.2011 PMID: 24449238
26. Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in "driver-negative" lung adenocarcinomas. Clin Cancer Res Off J Am Assoc Cancer Res. 2015; doi: 10.1158/1078-0432. CCR-14-2683
27. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012; 4: 136ra68. doi: 10.1126/scitranslmed.3003726 PMID: 22649089
28. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med. 2014; 6: 224ra24. doi: 10.1126/scitranslmed.3007094 PMID: 24553385
29. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014; 20: 548-54. doi: 10. 1038/nm.3519 PMID: 24705333
30. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Toward complete and accurate reporting of studies of diagnostic accuracy. The STARD initiative. Am J Clin Pathol. 2003; 119:18-22. doi: 10.1309/8exc-cm6y-r1th-ubaf PMID: 12520693
31. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med. 2009; 11: 3-14. doi: 10.1097/GIM.0b013e318184137c PMID: 18813139
32. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, et al. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Cancer Netw JNCCN. 2011; 9 Suppl 5: S1-32; quiz S33. PMID: 22138009
33. Gargis AS, Kalman L, Berry MW, Bick DP, Dimmock DP, Hambuch T, et al. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol. 2012; 30:1033-6. doi: 10. 1038/nbt.2403 PMID: 23138292
34. Aparicio S, Caldas C. The implications of clonal genome evolution for cancer medicine. N Engl J Med. 2013; 368: 842-851. doi: 10.1056/NEJMra1204892 PMID: 23445095
35. Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer J Int Cancer. 1998; 78: 766-774.
36. Zhao X, Weir BA, La Framboise T, Lin M, Beroukhim R, Garraway L, et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 2005; 65: 5561-5570. doi: 10.1158/0008-5472.CAN-04-4603 PMID: 15994928
37. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006; 10: 515-527. doi: 10.1016/j. ccr.2006.10.008 PMID: 17157791
38. Kubo T, Yamamoto H, Lockwood WW, Valencia I, Soh J, Peyton M, et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer J Int Cancer. 2009; 124:1778-1784. doi: 10.1002/ijc.24150
39. Licitra L, Perrone F, Tamborini E, Bertola L, Ghirelli C, Negri T, et al. Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2011; 22:1886-1893. doi: 10.1093/annonc/mdq756
40. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001; 409: 860-921. doi: 10.1038/35057062 PMID: 11237011
41. Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution. Cancer Discov. 2014; doi: 10.1158/2159-8290CD-14-0462 PMID: 25656907
42. Bidard F-C, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014; 15: 406-414. doi: 10.1016/S1470-2045(14)70069-5 PMID: 24636208
43. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNAto monitor metastatic breast cancer. N Engl J Med. 2013; 368:1199-209. doi: 10.1056/NEJMoa1213261 PMID: 23484797
44. Bidard F-C, Madic J, Mariani P, Piperno-Neumann S, Rampanou A, Servois V, et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer J Int Cancer. 2014; 134:1207-1213. doi: 10.1002/ijc.28436
45. Madic J, Kiialainen A, Bidard F-C, Birzele F, Ramey G, Leroy Q, et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer J Int Cancer. 2014; doi: 10.1002/ijc.29265
46. Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500. J Clin Oncol Off J Am Soc Clin Oncol. 2014; doi: 10.1200/JCO.2014.56.2561
47. de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 2014; 346: 251-256. doi: 10.1126/science.1253462 PMID: 25301630
48. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013; 369:1023-34. doi: 10.1056/NEJMoa1305275 PMID: 24024839
49. Oliveira C, Velho S, Moutinho C, Ferreira A, Preto A, Domingo E, et al. KRAS and BRAFoncogenic mutations in MSS colorectal carcinoma progression. Oncogene. 2007; 26:158-163. doi: 10.1038/sj. onc.1209758 PMID: 16953233
50. Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012; 30: 593-9. doi: 10.1200/JCO.2010.33.8889 PMID: 22124109
51. Oesterreich S, Davidson NE. The search for ESR1 mutations in breast cancer. Nat Genet. 2013; 45: 1415-6. doi: 10.1038/ng.2831 PMID: 24270445
52. Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, et al. Novel therapeutic strategies for patients with NSCLCthatdo not respond to treatment with EGFR inhibitors. Cancer Treat Rev. 2014; 40: 990-1004. doi: 10.1016/j.ctrv.2014.05.009 PMID: 24953979
53. Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, et al. Breast cancer version 3.2014. J Natl Compr Canc Netw. 2014; 12: 542-90. PMID: 24717572
54. Colon Cancer (Version 1.2015) [Internet]. 2014. Available: http://www.nccn.org/professionals/physician-gls/pdf/colon.pdf
55. Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE 3rd, et al. Melanoma, version 4.2014. J Natl Compr Canc Netw. 2014; 12: 621-9. PMID: 24812131
56. Younossi ZM, Teran JC, Ganiats TG, Carey WD. Ultrasound-guided liver biopsy for parenchymal liver disease: an economic analysis. 1998 Jan pp. 46-50.
57. Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143: e93S-120S. doi: 10.1378/chest.12-2351 PMID: 23649456
58. Overman MJ, Modak J, Kopetz S, Murthy R, Yao JC, Hicks ME, et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol Off J Am Soc Clin Oncol. 2013; 31: 17-22. doi: 10.1200/JCO.2012.43.1718
59. Accordino MK, Wright JD, Buono D, Neugut AI, Hershman DL. Trends in Use and Safety of Image-Guided Transthoracic Needle Biopsies in Patients With Cancer. J Oncol Pract Am Soc Clin Oncol. 2015; doi: 10.1200/JOP.2014.001891
60. Korst RJ, Gold HT, Kent MS, Port JL, Lee PC, Altorki NK. Surveillance computed tomography after complete resection for non-small cell lung cancer: results and costs. J Thorac Cardiovasc Surg. 2005; 129: 652-60. doi: 10.1016/j.jtcvs.2004.10.033 PMID: 15746751
61. Lokhandwala T., Dann R., Johnson M., D'Souza A. O. Costs of the Diagnostic Workup for Lung Cancer-A Medicare Claims Analysis [Abstract 3373]. Multidiscip Symp Thorac Oncol. 2014;
62. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976; 194: 23-28. PMID: 959840
63. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012; 120:1067-76. doi: 10.1182/blood-2012-01-405985 PMID: 22498740
64. Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010; 28: 4877-83. doi: 10.1200/JCO.2009.26.5983 PMID: 20921468
65. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012; 18: 6373-83. doi: 10.1158/1078-0432.CCR-12-1627 PMID: 22966018
66. Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine for patients with advanced cancer in the phase I program at MD anderson: validation and landmark analyses. Clin Cancer Res. 2014; 20: 4827-36. doi: 10.1158/1078-0432.CCR-14-0603 PMID: 24987059
67. Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, et al. Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. The Oncologist. 2014; 19: 631-636. doi: 10.1634/theoncologist.2013-0405 PMID: 24797821
68. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013; 31:1023-31. doi: 10.1038/nbt.2696 PMID: 24142049
69. Douillard JY, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, et al. Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol. 2014; 9: 1345-53. doi: 10.1097/jto.0000000000000263 PMID: 25122430
70. Zill OA, Greene C, Sebisanovic D, Siew L, Leng J, Vu M, et al. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015; doi: 10.1158/2159-8290.CD-15-0274 PMID: 26432108
71. Ko AH, Bekaii-Saab T, van Ziffle J, Mirzoeva OK, Joseph N, Talasaz A, et al. AMulticenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2015; doi: 10. 1158/1078-0432.CCR-15-0979
72. Taylor JM, Ankerst DP, Andridge RR. Validation of biomarker-based risk prediction models. Clin Cancer Res. 2008; 14: 5977-83. doi: 10.1158/1078-0432.CCR-07-4534 PMID: 18829476
73. Cappuzzo F, Ligorio C, Ligorio C, Toschi L, Rossi E, Trisolini R, et al. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2007; 2: 423-429. doi: 10.1097/01. JTO.0000268676.79872.9b
74. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012; 483: 100-103. doi: 10.1038/nature10868 PMID: 22281684
75. Lorusso G, Rüegg C. New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol. 2012; 22: 226-233. doi: 10.1016/j.semcancer.2012.03.007 PMID: 22504658
76. Bentley DR, Balasubramanian S, Swerdlow HP, Smith GP, Milton J, Brown CG, et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature. 2008; 456: 53-59. doi: 10. 1038/nature07517 PMID: 18987734
77. Norton SE, Lechner JM, Williams T, Fernando MR. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin Biochem. 2013; 46:1561-1565. doi: 10.1016/j.clinbiochem.2013.06.002 PMID: 23769817
78. Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Dressman D. BEAMing: single-molecule PCR on micro-particles in water-in-oil emulsions. Nat Methods. 2006; 3: 551-559. doi: 10.1038/nmeth898 PMID: 16791214
79. Victoria van Kets Maryke Appel, Kitzman Jacob, Snyder Matthew, Shendure Jay, Gray Phillip, et al. Kapa Hyper Prep: A next-generation kit for fast and efficient library construction from challenging DNA samples. [Abstract]. Adv Genome Biol Technol. 2014; Available: https://www.kapabiosystems.com/assets/AGBT-2014 Hyper-Prep Poster-Note.pdf
80. Altman DG, Bland JM. Diagnostic tests. 1: Sensitivity and specificity. BMJ. 1994; 308:1552. PMID: 8019315
81. Newcombe RG. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med. 1998; 17: 2635-2650. PMID: 9839354